Novartis AG EBITDA Margin 2010-2023 | NVS

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Novartis AG (NVS) over the last 10 years. The current EBITDA margin for Novartis AG as of December 31, 2023 is .
Novartis AG EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2023-12-31 $46.66B $18.15B 38.90%
2023-09-30 $46.02B $17.13B 37.23%
2023-06-30 $44.71B $16.10B 36.01%
2023-03-31 $43.86B $15.45B 35.23%
2022-12-31 $43.46B $14.91B 34.31%
2022-09-30 $50.20B $14.64B 29.16%
2022-06-30 $52.79B $14.28B 27.05%
2022-03-31 $53.00B $13.63B 25.72%
2021-12-31 $52.88B $11.69B 22.11%
2021-09-30 $56.14B $17.07B 30.41%
2021-06-30 $51.56B $14.09B 27.34%
2021-03-31 $49.88B $12.97B 25.99%
2020-12-31 $49.90B $13.30B 26.64%
2020-09-30 $45.83B $9.12B 19.90%
2020-06-30 $49.53B $12.60B 25.44%
2020-03-31 $49.93B $12.91B 25.85%
2019-12-31 $48.68B $12.41B 25.49%
2019-09-30 $47.86B $11.69B 24.42%
2019-06-30 $46.76B $10.20B 21.81%
2019-03-31 $46.39B $10.02B 21.59%
2018-12-31 $46.10B $10.22B 22.18%
2018-09-30 $47.37B $10.71B 22.61%
2018-06-30 $48.67B $10.83B 22.24%
2018-03-31 $49.51B $10.62B 21.45%
2017-12-31 $50.14B $10.10B 20.14%
2017-09-30 $49.58B $9.71B 19.59%
2017-06-30 $49.23B $11.13B 22.62%
2017-03-31 $49.41B $12.41B 25.12%
2016-12-31 $49.44B $14.31B 28.95%
2016-09-30 $49.63B $12.83B 25.86%
2016-06-30 $49.78B $12.65B 25.40%
2016-03-31 $50.00B $12.88B 25.75%
2015-12-31 $50.39B $13.12B 26.04%
2015-09-30 $50.94B $13.80B 27.09%
2015-06-30 $51.75B $14.11B 27.27%
2015-03-31 $52.81B $14.68B 27.81%
2014-12-31 $53.63B $14.55B 27.13%
2014-09-30 $52.60B $15.91B 30.24%
2014-06-30 $52.21B $15.65B 29.98%
2014-03-31 $51.54B $15.29B 29.66%
2013-12-31 $52.72B $15.45B 29.30%
2013-09-30 $49.87B $14.45B 28.98%
2013-06-30 $51.00B $14.98B 29.37%
2013-03-31 $52.26B $15.29B 29.25%
2012-12-31 $51.97B $15.08B 29.01%
2012-09-30 $57.49B $15.43B 26.83%
2012-06-30 $58.48B $15.62B 26.71%
2012-03-31 $59.07B $16.03B 27.13%
2011-12-31 $59.38B $16.76B 28.23%
2011-09-30 $58.84B $17.08B 29.02%
2011-06-30 $56.63B $16.52B 29.18%
2011-03-31 $53.43B $15.44B 28.91%
2010-12-31 $51.56B $15.10B 29.29%
2010-09-30 $50.24B $14.36B 28.58%
2010-06-30 $48.71B $13.78B 28.29%
2010-03-31 $47.53B $13.07B 27.50%
2009-12-31 $45.10B $11.69B 25.93%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $209.653B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01